Pharma-biotech pairings continued apace in the antibody-drug conjugate (ADC) space, with 2023 capped by Legochem Biosciences Inc. signing a $1.7 billion licensure deal with Johnson & Johnson arm ...
Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), licensed its ADC technology to BigHat Biosciences ...
New generation of Antibody-Drug Conjugates (ADCs) shows unprecedented promise in early-stage disease
Lugano/Berlin 18 October 2025 - In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs) ...
Multiple sessions at ESMO Congress 2024 covered antibody-drug conjugates (ADCs), which are an emerging therapy that holds great promise in cancer but comes with challenges. Antibody-drug conjugates ...
Debiopharm to present pre-clinical and clinical research advances in DDR inhibition, dual payload ADCs & AI-driven biomarkers at AACR 2026: Lausanne, Switzerland Thursday, April 1 ...
The very first antibody-drug conjugates (ADCs) to enter clinical evaluation sought to improve the therapeutic index of approved anti-cancer drugs, such as doxorubicin and vinblastine, by linking them ...
Antibody-drug conjugates (ADCs) have reshaped the cancer treatment landscape across a variety of different tumor types. ADCs' peculiar pharmacologic design combines the cytotoxic properties of ...
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores Lonza's commitment to helping customers deliver ...
Debiopharm presents new DDR, dual‑payload ADC and AI biomarker research at AACR 2026, including first clinical data from the MYTHIC study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results